Literature DB >> 24659044

Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions.

Hanan AlSaeid Alshenawy1.   

Abstract

Differentiating the follicular derived lesions can be challenging. Although immunohistochemistry is generally accepted as a useful ancillary technique in the diagnosis, controversy exists regarding the best marker or combination of markers to distinguish each lesion from its mimics. In this study, we aimed at evaluating multiple markers to compare their sensitivity and usefulness, and to find out if a combination of the evaluated markers can be of additional value in discriminating thyroid lesions. The study included two groups of follicular derived thyroid lesions; benign group (Grave's disease, nodular goiter, Hashimoto's and adenoma) and malignant group (papillary, follicular carcinoma, well differentiated tumors of unknown malignant potential and follicular tumour of unknown malignant potential). Immunohistochemical evaluation of CD56, HBME-1, Gaectin-3 and CK19 were done. The sensitivity, specificity for each marker and their combination were calculated. Each marker was sensitive and specific for certain lesion but the sensitivity and specificity was increased when use combination of markers. Although no single marker is completely sensitive and specific for follicular thyroid lesions, the combination of CD56, HBME-1, Gaectin-3 and CK19 attains high sensitivity and specificity in diagnosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24659044     DOI: 10.1007/s12253-014-9760-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  33 in total

1.  Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma.

Authors:  John K C Chan
Journal:  Am J Clin Pathol       Date:  2002-01       Impact factor: 2.493

2.  HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.

Authors:  Yasuhiro Ito; Hiroshi Yoshida; Chisato Tomoda; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kennichi Kakudo; Kanji Kuma; Akira Miyauchi
Journal:  Anticancer Res       Date:  2005 Jan-Feb       Impact factor: 2.480

3.  Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.

Authors:  P S de Matos; A P Ferreira; F de Oliveira Facuri; L V M Assumpção; K Metze; L S Ward
Journal:  Histopathology       Date:  2005-10       Impact factor: 5.087

4.  Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.

Authors:  Jeffrey Liu; Bhuvanesh Singh; Giovanni Tallini; Diane L Carlson; Nora Katabi; Ashok Shaha; R Michael Tuttle; Ronald A Ghossein
Journal:  Cancer       Date:  2006-09-15       Impact factor: 6.860

5.  Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours.

Authors:  M Miettinen; P Kärkkäinen
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

6.  Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.

Authors:  E Saggiorato; R De Pompa; M Volante; S Cappia; F Arecco; A P Dei Tos; F Orlandi; M Papotti
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

7.  Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules.

Authors:  Rasha M Abd El Atti; Lobna S Shash
Journal:  J Egypt Natl Canc Inst       Date:  2012-11-06

8.  Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.

Authors:  Ying Y Liu; Hans Morreau; Job Kievit; Johannes A Romijn; Nancy Carrasco; Johannes W Smit
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

9.  The investigation of galectin-3 in diseases of the thyroid gland.

Authors:  Rita Beáta Kovács; János Földes; Gábor Winkler; Miklós Bodó; Zoltán Sápi
Journal:  Eur J Endocrinol       Date:  2003-11       Impact factor: 6.664

10.  Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid.

Authors:  Dina El Demellawy; Ahmed Nasr; Salem Alowami
Journal:  Diagn Pathol       Date:  2008-02-06       Impact factor: 2.644

View more
  3 in total

Review 1.  Pathology Reporting of Thyroid Core Needle Biopsy: A Proposal of the Korean Endocrine Pathology Thyroid Core Needle Biopsy Study Group.

Authors:  Chan Kwon Jung; Hye Sook Min; Hyo Jin Park; Dong Eun Song; Jang Hee Kim; So Yeon Park; Hyunju Yoo; Mi Kyung Shin
Journal:  J Pathol Transl Med       Date:  2015-07-15

2.  How microgravity changes galectin-3 in thyroid follicles.

Authors:  Elisabetta Albi; Francesco Curcio; Andrea Lazzarini; Alessandro Floridi; Samuela Cataldi; Remo Lazzarini; Elisabetta Loreti; Ivana Ferri; Francesco Saverio Ambesi-Impiombato
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

Review 3.  Core Needle Biopsy of the Thyroid: 2016 Consensus Statement and Recommendations from Korean Society of Thyroid Radiology.

Authors:  Dong Gyu Na; Jung Hwan Baek; So Lyung Jung; Ji-Hoon Kim; Jin Yong Sung; Kyu Sun Kim; Jeong Hyun Lee; Jung Hee Shin; Yoon Jung Choi; Eun Ju Ha; Hyun Kyung Lim; Soo Jin Kim; Soo Yeon Hahn; Kwang Hwi Lee; Young Jun Choi; Inyoung Youn; Young Joong Kim; Hye Shin Ahn; Ji Hwa Ryu; Seon Mi Baek; Jung Suk Sim; Chan Kwon Jung; Joon Hyung Lee
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.